Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 18.
doi: 10.1111/ijd.17795. Online ahead of print.

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares: An Observational, Retrospective, and Multicenter Study of Effectiveness and Safety in Real-World Clinical Practice

Elena Canal-Garcia  1 , Elena Del Alcázar-Viladomiu  1 , Rosa María Izu  2 , Mar Llamas-Velasco  3 , Javier Alcántara-González  4 , Adrián Ballano-Ruiz  5 , Tamara Gracia-Cazaña  6 , María García-Sánchez  7 , Amalia Pérez-Gil  8 , Juan Antonio Ratón-Nieto  9 , Raquel Rivera-Díaz  10 , Antonio Sahuquillo-Torralba  11 , Celia Sanchis-Sánchez  12 , José Manuel Carrascosa  1
Affiliations

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares: An Observational, Retrospective, and Multicenter Study of Effectiveness and Safety in Real-World Clinical Practice

Elena Canal-Garcia et al. Int J Dermatol. .
No abstract available

Keywords: IL‐36 pathway; generalized pustular psoriasis; spesolimab; systemic inflammation.

PubMed Disclaimer

References

    1. R. Rivera‐Díaz, E. Daudén, J. M. Carrascosa, P. Cueva, and L. Puig, “Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment,” Dermatology and Therapy 13, no. 3 (2023): 673–688, https://doi.org/10.1007/s13555‐022‐00881‐0.
    1. A. Morita, B. Strober, A. D. Burden, et al., “Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): An International, Multicentre, Randomised, Placebo‐Controlled Trial,” Lancet 402, no. 10412 (2023): 1541–1551, https://doi.org/10.1016/S0140‐6736(23)01378‐8.
    1. H. Bachelez, S. E. Choon, S. Marrakchi, et al., “Trial of Spesolimab for Generalized Pustular Psoriasis,” New England Journal of Medicine 385, no. 26 (2021): 2431–2440.
    1. J. Yeung and S. Sood, “Real‐World Experience of Spesolimab for Generalized Pustular Psoriasis Flares in Adult Patients: A Multicenter Retrospective Study,” American Journal of Clinical Dermatology 26, no. 1 (2025): 151–153.
    1. D. Bernardo, D. Thaçi, and T. Torres, “Spesolimab for the Treatment of Generalized Pustular Psoriasis,” Drugs 84, no. 1 (2024): 45–58, https://doi.org/10.1007/s40265‐023‐01988‐0.

LinkOut - more resources